Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
11
Recruiting, industry sponsors, Gastroenterology and liver, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed197
11 trials
Showing 1 to 11, recently updated first.
- A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Pivotal-lookingRecruiting
Eupraxia Pharmaceuticals Inc.Industry
NCT05608681 · 117 participants (planned) · Start Mar 31, 2023 · Primary completion Dec 2026
Drug: EP-104GI · For: Eosinophilic Esophagitis
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 33 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07358546 · 32 participants (planned) · Start Mar 13, 2026 · Primary completion Oct 13, 2027
Drug: Efimosfermin alfa · For: Non-alcoholic Fatty Liver Disease
Sites: Rialto, California; Miami Lakes, Florida; Tampa, Florida · 5 sites in all
Zydus Therapeutics Inc.Industry
NCT06825559 · 6 participants (planned) · Start Aug 5, 2025 · Primary completion Dec 31, 2026
Drug: Saroglitazar Magnesium 1 mg · For: Cholestatic Liver Disease
Sites: Indianapolis, Indiana
EccogeneIndustry
NCT07726368 · 40 participants (planned) · Start Aug 7, 2026 · Primary completion Dec 2026
Drug: ECC4703; Sulfasalazine and 1 more · For: Non-alcoholic Fatty Liver Disease (NAFLD); Dyslipidaemia
Sites: Melbourne, Australia
Sunshine Lake Pharma Co., Ltd.Industry
NCT07099118 · 96 participants (planned) · Start Sep 3, 2025 · Primary completion Dec 30, 2026
Drug: HEC169584 capsule; placebo · For: Non - Alcoholic Steatohepatitis
Sites: Beijing, China
- A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan GluratePivotal-lookingRecruiting
Cinclus Pharma Holding ABIndustry
NCT05469854 · 121 participants (planned) · Start Jul 13, 2022 · Primary completion Nov 30, 2026
Drug: Linaprazan glurate; Placebo · For: Pharmacokinetics; Cardiodynamic ECG; Safety, and Tolerability and 1 more
Sites: Uppsala, Sweden
- A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05648214 · 172 participants (planned) · Start Dec 27, 2022 · Primary completion Aug 10, 2027
Drug: ALN-PNP; Placebo (PB) · For: Healthy Volunteers; Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Sites: Glendale, California; Los Angeles, California; Miami, Florida · 6 sites in all
Valenta Pharm JSCIndustry
NCT07421011 · 36 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2026
Drug: Trimedat® · For: Irritable Bowel Syndrome; Gallstone Disease; GERD and 2 more
Sites: Saint Petersburg, Russia
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT07128797 · 32 participants (planned) · Start Jul 24, 2025 · Primary completion Jun 2026
Drug: B1344 · For: NAFLD (Non-alcoholic Fatty Liver Disease); NASH (Nonalcoholic Steatohepatitis)
Sites: Beijing, China; Guangzhou, China; Datong, China · 5 sites in all
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy SubjectsPivotal-lookingRecruiting
Changchun Intellicrown Pharmaceutical Co. LTDIndustry
NCT06216041 · 138 participants (planned) · Start Dec 6, 2023 · Primary completion Jun 1, 2025
Drug: IMM-H014; Placebo and 2 more · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Changchun, China
1Globe Health InstituteIndustry
NCT06694935 · 52 participants (planned) · Start Jan 6, 2025 · Primary completion Jul 2025
Drug: QX1206 · For: Type 2 Diabetes Mellitus (T2DM); Non-Alcoholic Fatty Liver Disease (NAFLD)
Sites: Toronto, Canada
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.